Fluorescence-Based Laser Capture Microscopy Technology Facilitates Identification of Critical In Vivo Cytomegalovirus Transcriptional Programs

  • Craig N. Kreklywich
  • Patricia P. Smith
  • Carmen Baca Jones
  • Anda Cornea
  • Susan L. Orloff
  • Daniel N. StreblowEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1119)


Cytomegalovirus gene expression in highly permissive, cultured fibroblasts occurs in three kinetic classes known as immediate early, early, and late. Infection of these cells results in a predictable transcriptional program leading to high levels of virus production. Infection of other, so-called, nonpermissive cell types results in a transcriptional program that either fails to produce virus particles or production is substantially reduced compared to fibroblasts. We have found that CMV gene expression profiles in tissues from infected hosts differ greatly from those observed in infected tissue culture cells. The number of viral genes expressed in tissues is much more limited, and the number of highly active genes does not correlate with viral DNA load. Additionally, viral gene expression in vivo is tissue selective with no two tissues expressing the exact same viral gene profile. Thus, in vivo CMV gene expression appears to be governed by mechanisms that are still uncharacterized. Cytomegalovirus remains in a persistent phase for the lifetime of the host. During this phase only a limited number of host cells are infected, and it is very difficult to detect CMV gene expression in whole tissues without sub-fractionating infected vs. uninfected cells. Herein, we describe the development of a fluorescence-based laser capture microscopy technique coupled with small sample size microarray analysis to determine the viral gene expression in 50–100 infected cells isolated from frozen RCMV-infected tissue sections.

Key words

Laser capture microscopy Cytomegalovirus Green fluorescence protein Microarray analysis 



The work presented in this manuscript was supported by grants from the National Institutes of Health (HL-083194 DNS) and (HL-66238-01 SLO). The Arcturus laser capture microscope used for this study was supported by Award Number S10 RR027503 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. The Oregon National Primate Research Center Imaging Core is supported by NIH P51 RR000163. We thank Andrew Townsend for his assistance with graphics.


  1. 1.
    Britt W (2008) Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol 325:417–470PubMedGoogle Scholar
  2. 2.
    Chee MS, Bankier AT, Beck S, Bohni R, Browne CM, Cerny R, Horsnell T, Hutchison CA III, Kouzarides T, Martignetti JA, Preddie E, Satchwell SC, Tomlinson P, Weston KM, Barrell BG (1990) Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. In: McDougall JK (ed) Cytomegaloviruses. Springer, Berlin, pp 125–171CrossRefGoogle Scholar
  3. 3.
    Davison AJ, Dolan A, Akter P, Addison C, Dargan DJ, Alcendor DJ, McGeoch DJ, Hayward GS (2003) The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol 84:17–28PubMedCrossRefGoogle Scholar
  4. 4.
    Chambers J, Angulo A, Amaratunga D, Guo H, Jiang Y, Wan JS, Bittner A, Frueh K, Jackson MR, Peterson PA, Erlander MG, Ghazal P (1999) DNA microarrays of the complex human cytomegalovirus genome: profiling kinetic class with drug sensitivity of viral gene expression. J Virol 73:5757–5766PubMedCentralPubMedGoogle Scholar
  5. 5.
    Goodrum F, Jordan CT, Terhune SS, High K, Shenk T (2004) Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulations. Blood 104:687–695PubMedCrossRefGoogle Scholar
  6. 6.
    Goodrum FD, Jordan CT, High K, Shenk T (2002) Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proc Natl Acad Sci U S A 99:16255–16260PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Goodrum F, Reeves M, Sinclair J, High K, Shenk T (2007) Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 110:937–945PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Petrucelli A, Rak M, Grainger L, Goodrum F (2009) Characterization of a novel Golgi apparatus-localized latency determinant encoded by human cytomegalovirus. J Virol 83:5615–5629PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Streblow DN, van Cleef KW, Kreklywich CN, Meyer C, Smith P, Defilippis V, Grey F, Fruh K, Searles R, Bruggeman C, Vink C, Nelson JA, Orloff SL (2007) Rat cytomegalovirus gene expression in cardiac allograft recipients is tissue specific and does not parallel the profiles detected in vitro. J Virol 81:3816–3826PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Bradley AJ, Lurain NS, Ghazal P, Trivedi U, Cunningham C, Baluchova K, Gatherer D, Wilkinson GW, Dargan DJ, Davison AJ (2009) High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. J Gen Virol 90:2375–2380PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Gatherer D, Seirafian S, Cunningham C, Holton M, Dargan DJ, Baluchova K, Hector RD, Galbraith J, Herzyk P, Wilkinson GW, Davison AJ (2011) High-resolution human cytomegalovirus transcriptome. Proc Natl Acad Sci U S A 108:19755–19760PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS (1993) Risk factors for chronic rejection in renal allograft recipients. Transplantation 55:752–756, discussion 6–7PubMedCrossRefGoogle Scholar
  13. 13.
    Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE (1989) Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 261:3561–3566PubMedCrossRefGoogle Scholar
  14. 14.
    Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62:3347–3350PubMedGoogle Scholar
  15. 15.
    Melnick JL, Adam E, Debakey ME (1993) Cytomegalovirus and atherosclerosis. Eur Heart J 14(Suppl K):30–38PubMedGoogle Scholar
  16. 16.
    Muhlestein JB, Horne BD, Carlquist JF, Madsen TE, Bair TL, Pearson RR, Anderson JL (2000) Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 102:1917–1923PubMedCrossRefGoogle Scholar
  17. 17.
    Baca Jones CC, Kreklywich CN, Messaoudi I, Vomaske J, McCartney E, Orloff SL, Nelson JA, Streblow DN (2009) Rat cytomegalovirus infection depletes MHC II in bone marrow derived dendritic cells. Virology 388:78–90PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Minamishima I, Ueda K, Minematsu T, Minamishima Y, Umemoto M, Take H, Kuraya K (1994) Role of breast milk in acquisition of cytomegalovirus infection. Microbiol Immunol 38:549–552PubMedCrossRefGoogle Scholar
  19. 19.
    Orloff SL, Hwee YK, Kreklywich C, Andoh TF, Hart E, Smith PA, Messaoudi I, Streblow DN (2011) Cytomegalovirus latency promotes cardiac lymphoid neogenesis and accelerated allograft rejection in CMV naive recipients. Am J Transplant 11:45–55PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Orloff SL, Streblow DN, Soderberg-Naucler C, Yin Q, Kreklywich C, Corless CL, Smith PA, Loomis CB, Mills LK, Cook JW, Bruggeman CA, Nelson JA, Wagner CR (2002) Elimination of donor-specific alloreactivity prevents cytomegalovirus-accelerated chronic rejection in rat small bowel and heart transplants. Transplantation 73:679–688PubMedCrossRefGoogle Scholar
  21. 21.
    Streblow DN, Kreklywich C, Yin Q, De La Melena VT, Corless CL, Smith PA, Brakebill C, Cook JW, Vink C, Bruggeman CA, Nelson JA, Orloff SL (2003) Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants. J Virol 77:2182–2194PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Streblow DN, Kreklywich CN, Andoh T, Moses AV, Dumortier J, Smith PP, Defilippis V, Fruh K, Nelson JA, Orloff SL (2008) The role of angiogenic and wound repair factors during CMV-accelerated transplant vascular sclerosis in rat cardiac transplants. Am J Transplant 8:277–287PubMedCrossRefGoogle Scholar
  23. 23.
    Streblow DN, Kreklywich CN, Smith P, Soule JL, Meyer C, Yin M, Beisser P, Vink C, Nelson JA, Orloff SL (2005) Rat cytomegalovirus-accelerated transplant vascular sclerosis is reduced with mutation of the chemokine-receptor R33. Am J Transplant 5:436–442PubMedCrossRefGoogle Scholar
  24. 24.
    Qin JY, Zhang L, Clift KL, Hulur I, Xiang AP, Ren BZ, Lahn BT (2010) Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One 5:e10611PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Nevels M, Nitzsche A, Paulus C (2011) How to control an infectious bead string: nucleosome-based regulation and targeting of herpesvirus chromatin. Rev Med Virol 21:154–180PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Craig N. Kreklywich
    • 1
    • 2
  • Patricia P. Smith
    • 1
  • Carmen Baca Jones
    • 1
  • Anda Cornea
    • 4
  • Susan L. Orloff
    • 1
    • 2
    • 3
  • Daniel N. Streblow
    • 1
    Email author
  1. 1.Department of Molecular Microbiology & ImmunologyVaccine & Gene Therapy Institute, Oregon Health & Science UniversityBeavertonUSA
  2. 2.Department of SurgeryOregon Health & Science UniversityPortlandUSA
  3. 3.Portland VA Medical CenterPortlandUSA
  4. 4.Oregon National Primate Research CenterOregon Health & Science UniversityBeavertonUSA

Personalised recommendations